# A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

> **NCT02514551** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 245 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02514551
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-12
- **Primary completion:** 2017-10-27
- **Final completion:** 2018-12-28
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514551, "A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02514551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*